Neurocognitive Disorders

  • Rajesh R. Tampi
  • Deena J. Tampi
  • Wynnelena C. Canio
  • Poorvanshi Alag
  • Dhweeja Dasarathy
  • Joel P. Dey


Mild neurocognitive disorder is thought to be an intermediate stage between normal age-associated cognitive changes and major neurocognitive disorder. Individuals with mild neurocognitive disorder have a faster rate of progression to major neurocognitive disorder than age-matched controls. Known risk factors for progression to major neurocognitive disorder include greater cognitive deficits at baseline, the presence of the APOE4 carrier gene, greater brain volume changes, cerebrospinal fluid changes, and the presence of neuropsychiatric symptoms. Current data indicates that the progression of mild neurocognitive disorder to major neurocognitive disorder can be delayed through the use of cognitive and physical training. Unfortunately, studies of pharmacotherapeutic agents do not indicate any benefit for cholinesterase inhibitors, the anti-inflammatory drug rofecoxib, and antioxidants in slowing the progression of mild neurocognitive disorder to major neurocognitive disorder.


  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013. p. 299–320.CrossRefGoogle Scholar
  2. 2.
    Reisberg B, Ferris SH, Kluger A, et al. Mild cognitive impairment (MCI): a historical perspective. Int Psychogeriatr. 2008;20(1):18–31.PubMedGoogle Scholar
  3. 3.
    Reisberg B, Ferris SH, de Leon MJ. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Reisberg B, Ferris SH, de Leon MJ, et al. The stage specific temporal cause of Alzheimer’s disease: functional and behavioral concomitants based upon cross-sectional and longitudinal observation. Prog Clin Biol Res. 1989;317:23–41.PubMedGoogle Scholar
  5. 5.
    Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41(7):1006–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer’s disease. Arch Neurol. 2001;58(3):397–405.CrossRefPubMedGoogle Scholar
  8. 8.
    Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Petersen RC. Mild cognitive impairment. Continuum. 2016;22(2 Dementia):404–18.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010;75(10):889–97.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Stephan BC, Hunter S, Harris D, et al. The neuropathological profile of mild cognitive impairment (MCI): a systematic review. Mol Psychiatry. 2012;17(11):1056–76.CrossRefPubMedGoogle Scholar
  12. 12.
    Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer’s disease pathology and cerebral infarctions. Neurology. 2005;64:834–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Fennema-Notestine C, McEvoy LK, Hagler DJ, et al. The Alzheimer’s disease neuroimaging initiative. Structural neuroimaging in the detection and prognosis of pre-clinical and early AD. Behav Neurol. 2009;21(1):3–12.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Koivunen J, Pirttilä T, Kemppainen N, et al. PET amyloid ligand [11C] PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord. 2008;26(4):378–83.CrossRefPubMedGoogle Scholar
  16. 16.
    Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type. An epidemiologic study. Neurology. 2004;63(1):115–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56(1):37–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59(10):1594–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Gauthier S, Reisberg B, Zaudig M, et al. International Psychogeriatric Association Expert Conference on mild cognitive impairment. Lancet. 2006;367(9518):1262–70.CrossRefPubMedGoogle Scholar
  22. 22.
    Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr. 2008;13(1):45–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Petersen RC, Caracciolo B, Brayne C, et al. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275(3):214–28.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Jack CR, Petersen RC, YC X, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52(7):1397–403.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Jack CR, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65(8):1227–31.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Leung KK, Bartlett JW, Barnes J, et al. Cerebral atrophy in mild cognitive impairment and Alzheimer disease. Rates and acceleration. Neurology. 2013;80(7):648–54.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Herholz K. Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease. Expert Rev Neurother. 2010;10(11):1667–73.CrossRefPubMedGoogle Scholar
  28. 28.
    Ewers M, Walsh C, Trojanowski JQ, Shaw LM, et al. Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging. 2012;33(7):1203–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. Neurology. 2004;62(7):1199–201.CrossRefPubMedGoogle Scholar
  30. 30.
    Palmer K, Berger AK, Monastero R, et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology. 2007;68(19):1596–602.CrossRefPubMedGoogle Scholar
  31. 31.
    Butters MA, Young JB, Lopez O, et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci. 2008;10(3):345–57.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Robert PH, Berr C, Volteau M, et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: a one-year follow-up study. Clin Neurol Neurosurg. 2006;108(8):733–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Rosenberg PB, Mielke MM, Appleby B, et al. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry. 2011;26(4):364–72.CrossRefPubMedGoogle Scholar
  34. 34.
    Daly E, Zaitchik D, Copeland M, et al. Predicting conversion to Alzheimer’s disease using standardized clinical information. Arch Neurol. 2000;57(5):675–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227–34.CrossRefPubMedGoogle Scholar
  36. 36.
    Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46(1):149–54.CrossRefPubMedGoogle Scholar
  37. 37.
    Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA. 1995;273(16):1274–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Massoud F, Belleville S, Bergman H, et al. Mild cognitive impairment and cognitive impairment, no dementia: part B, therapy. Alzheimers Dement. 2007;3(4):283–91.CrossRefPubMedGoogle Scholar
  39. 39.
    Jean L, Bergeron ME, Thivierge S, Simard M. Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature. Am J Geriatr Psychiatry. 2010;18(4):281–96.CrossRefPubMedGoogle Scholar
  40. 40.
    Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300(9):1027–37.CrossRefPubMedGoogle Scholar
  41. 41.
    Li H, Li J, Li N, et al. Cognitive intervention for persons with mild cognitive impairment: a meta-analysis. Ageing Res Rev. 2011;10(2):285–96.CrossRefPubMedGoogle Scholar
  42. 42.
    Reijnders J, van Heugten C, van Boxtel M. Cognitive interventions in healthy older adults and people with mild cognitive impairment: a systematic review. Ageing Res Rev. 2013;12(1):263–75.CrossRefPubMedGoogle Scholar
  43. 43.
    Etgen T, Sander D, Bickel H, Förstl H. Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int. 2011;108(44):743–50.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Raschetti R, Albanese E, Vanacore N, et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 2007;4(11):e338.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Diniz BS, Pinto JA, Gonzaga ML, et al. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2009;259(4):248–56.CrossRefPubMedGoogle Scholar
  46. 46.
    Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204–15.CrossRefPubMedGoogle Scholar
  47. 47.
    Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. New Engl J Med. 2005;352(23):2379–88.CrossRefPubMedGoogle Scholar
  48. 48.
    Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry. 2013;203(3):255–64.CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta. 2012;1822(5):631–8.CrossRefPubMedGoogle Scholar
  50. 50.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013. p. 285–320.CrossRefGoogle Scholar
  51. 51.
    New Diagnostic Criteria for Alzheimer’s Disease. Accessed 1 Mar 2017.
  52. 52.
    Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75.CrossRefPubMedGoogle Scholar
  53. 53.
    Sousa RM, Ferri CP, Acosta D, et al. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet. 2009;374(9704):1821–30.CrossRefPubMedCentralPubMedGoogle Scholar
  54. 54.
    Sousa RM, Ferri CP, Acosta D, et al. The contribution of chronic diseases to the prevalence of dependence among older people in Latin America, China and India: a 10/66 Dementia Research Group population-based survey. BMC Geriatr. 2010;10:53.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148(6):427–34.CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83.CrossRefPubMedCentralPubMedGoogle Scholar
  57. 57.
    Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30(3):421–42.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Fiest KM, Jetté N, Roberts JI, et al. The Prevalence and Incidence of Dementia: a Systematic Review and Meta-analysis. Can J Neurol Sci. 2016;43:S3–S50.CrossRefPubMedGoogle Scholar
  59. 59.
    Anstey KJ, Eramudugolla R, Hosking DE, et al. Bridging the Translation Gap: from Dementia Risk Assessment to Advice on Risk Reduction. J Prev Alzheimers Dis. 2015;2:189–98.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Morris MC, Tangney CC, Wang Y, et al. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015;11(9):1015–22.CrossRefPubMedCentralPubMedGoogle Scholar
  61. 61.
    Abete P, Della-Morte D, Gargiulo G, et al. Cognitive impairment and cardiovascular diseases in the elderly. A heart-brain continuum hypothesis. Ageing Res Rev. 2014;18:41–52.CrossRefPubMedGoogle Scholar
  62. 62.
    Billioti de Gage S, Pariente A, Bégaud BI. there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf. 2015;14(5):733–47.CrossRefPubMedGoogle Scholar
  63. 63.
    Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.CrossRefPubMedCentralPubMedGoogle Scholar
  64. 64.
    Tannenbaum C, Paquette A, Hilmer S, et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging. 2012;29(8):639–58.PubMedGoogle Scholar
  65. 65.
    Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015;86(12):1299–306.PubMedGoogle Scholar
  66. 66.
    Henderson VW. Action of estrogens in the aging brain: dementia and cognitive aging. Biochim Biophys Acta. 2010;1800(10):1077–83.CrossRefPubMedGoogle Scholar
  67. 67.
    Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer’s disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 2007;23(3):194–201.CrossRefPubMedGoogle Scholar
  68. 68.
    McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;7(4):CD004034.Google Scholar
  69. 69.
    Imbimbo BP. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer’s disease. Expert Opin Investig Drugs. 2009;18(8):1147–68.CrossRefPubMedGoogle Scholar
  70. 70.
    Dá Mesquita S, Ferreira AC, Sousa JC, et al. Insights on the pathophysiology of Alzheimer’s disease: the crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neurosci Biobehav Rev. 2016;68:547–62.CrossRefPubMedGoogle Scholar
  71. 71.
    Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–1.CrossRefPubMedGoogle Scholar
  72. 72.
    O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698–706.CrossRefPubMedGoogle Scholar
  73. 73.
    Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844–66.CrossRefPubMedGoogle Scholar
  74. 74.
    Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672–82.CrossRefPubMedGoogle Scholar
  75. 75.
    Perry DC, Miller BL. Frontotemporal dementia. Semin Neurol. 2013;33(4):336–41.CrossRefPubMedGoogle Scholar
  76. 76.
    Mayo MC, Bordelon Y. Dementia with Lewy bodies. Semin Neurol. 2014;34(2):182–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Walker Z, Possin KL, Boeve BF, et al. Lewy body dementias. Lancet. 2015;386(10004):1683–97.CrossRefPubMedCentralPubMedGoogle Scholar
  78. 78.
    Jing W, Willis R, Feng Z. Factors influencing quality of life of elderly people with dementia and care implications: a systematic review. Arch Gerontol Geriatr. 2016;66:23–41.CrossRefPubMedGoogle Scholar
  79. 79.
    Kua EH, Ho E, Tan HH, et al. The natural history of dementia. Psychogeriatrics. 2014;14(3):196–201.CrossRefPubMedGoogle Scholar
  80. 80.
    Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis. 2007;4(6):428–30.CrossRefPubMedGoogle Scholar
  81. 81.
    Darrow MDA. practical approach to dementia in the outpatient primary care setting. Prim Care. 2015;42(2):195–204.CrossRefPubMedGoogle Scholar
  82. 82.
    Tsoi KK, Chan JY, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(9):1450–8.CrossRefPubMedGoogle Scholar
  83. 83.
    Feliciano L, Horning SM, Klebe KJ, et al. Utility of the SLUMS as a cognitive screening tool among a nonveteran sample of older adults. Am J Geriatr Psychiatry. 2013;21(7):623–30.CrossRefPubMedGoogle Scholar
  84. 84.
    Feldman HH, Jacova C, Robillard A, et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ. 2008;178(7):825–36.CrossRefPubMedCentralPubMedGoogle Scholar
  85. 85.
    Narayanan L, Murray AD. What can imaging tell us about cognitive impairment and dementia? World J Radiol. 2016;8(3):240–54.CrossRefPubMedCentralPubMedGoogle Scholar
  86. 86.
    Burrell JR, Piguet O. Lifting the veil: how to use clinical neuropsychology to assess dementia. J Neurol Neurosurg Psychiatry. 2015;86(11):1216–24.CrossRefPubMedGoogle Scholar
  87. 87.
    Sancesario GM, Bernardini S. How many biomarkers to discriminate neurodegenerative dementia? Crit Rev. Clin Lab Sci. 2015;52(6):314–26.CrossRefGoogle Scholar
  88. 88.
    Downing LJ, Caprio TV, Lyness JM. Geriatric psychiatry review: differential diagnosis and treatment of the 3 D’s - delirium, dementia, and depression. Curr Psychiatry Rep. 2013;15(16):365.CrossRefPubMedGoogle Scholar
  89. 89.
    Shatenstein B, Barberger-Gateau P, Mecocci P. Prevention of age-related cognitive decline: which strategies, when, and for whom? J Alzheimers Dis. 2015;48(1):35–53.CrossRefPubMedGoogle Scholar
  90. 90.
    Cheng ST. Cognitive reserve and the prevention of dementia: the role of physical and cognitive activities. Curr Psychiatry Rep. 2016;18(9):85.CrossRefPubMedCentralPubMedGoogle Scholar
  91. 91.
    Norton S, Matthews FE, Barnes DE, et al. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.CrossRefPubMedGoogle Scholar
  92. 92.
    Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–28.CrossRefPubMedCentralPubMedGoogle Scholar
  93. 93.
    Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76:27–50.Google Scholar
  94. 94.
    Tan CC, Yu JT, Wang HF, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Alzheimer Dis. 2014;41(2):615–31.Google Scholar
  95. 95.
    Tsoi KK, Chan JY, Leung NW, et al. Combination therapy showed limited superiority over monotherapy for Alzheimer disease: a meta-analysis of 14 randomized trials. J Am Med Dir Assoc. 2016;17(9):863.e1–8.Google Scholar
  96. 96.
    Atri A, Hendrix SB, Pejović V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):28.CrossRefPubMedCentralPubMedGoogle Scholar
  97. 97.
    Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782–92.CrossRefPubMedGoogle Scholar
  98. 98.
    Nardell M, Tampi RR. Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29(2):123–32.CrossRefPubMedGoogle Scholar
  99. 99.
    Stinton C, McKeith I, Taylor JP, et al. Pharmacological Management of Lewy Body Dementia: a Systematic Review and Meta-Analysis. Am J Psychiatry. 2015;172(8):731–42.CrossRefPubMedGoogle Scholar
  100. 100.
    Sarva H, Henchcliffe C. Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis. Ther Adv Neurol Disord. 2016;9(6):462–73.CrossRefPubMedCentralPubMedGoogle Scholar
  101. 101.
    Bharucha AJ, Rosen J, Mulsant BH, et al. Assessment of behavioral and psychological symptoms of dementia. CNS Spectr. 2002;7(11):797–802.CrossRefPubMedGoogle Scholar
  102. 102.
    Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708–14.CrossRefPubMedGoogle Scholar
  103. 103.
    Margallo-Lana M, Swann A, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry. 2001;16(1):39–44.CrossRefPubMedGoogle Scholar
  104. 104.
    Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44(9):1078–81.CrossRefPubMedGoogle Scholar
  105. 105.
    Lyketsos CG, Olin J. Depression in Alzheimer’s disease: overview and treatment. Biol Psychiatry. 2002;52(3):243–52.CrossRefPubMedGoogle Scholar
  106. 106.
    Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. I: disorders of thought content. Br J Psychiatry. 1990;157:72–6, 92–4CrossRefPubMedGoogle Scholar
  107. 107.
    Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257–63.CrossRefPubMedGoogle Scholar
  108. 108.
    Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46:130–5.CrossRefPubMedGoogle Scholar
  109. 109.
    Lee HB, Lyketsos CG. Depression in Alzheimer’s disease: heterogeneity and related issues. Biol Psychiatry. 2003;54(3):353–62.CrossRefPubMedGoogle Scholar
  110. 110.
    Olin JT, Katz IR, Meyers BS, et al. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002;10(2):129–41.CrossRefPubMedGoogle Scholar
  111. 111.
    Pearlson GD, Ross CA, Lohr WD, et al. Association between family history of affective disorder and the depressive syndrome of Alzheimer’s disease. Am J Psychiatry. 1990;37:452–6.Google Scholar
  112. 112.
    Rose KM, Lorenz R. Sleep disturbances in dementia. J Gerontol Nurs. 2010;36(5):9.CrossRefPubMedCentralPubMedGoogle Scholar
  113. 113.
    White H, Pieper C, Schmader K. The association of weight change in Alzheimer’s disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998;46(10):1223–7.CrossRefPubMedGoogle Scholar
  114. 114.
    Black B, Muralee S, Tampi RR. Inappropriate sexual behaviors in dementia. J Geriatr Psychiatry Neurol. 2005;18(3):155–62.CrossRefPubMedGoogle Scholar
  115. 115.
    Zubenko GS, Moossy J, Martinez J, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619–24.CrossRefPubMedGoogle Scholar
  116. 116.
    Victoroff J, Zarow C, Mack WJ, et al. Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer’s disease. Arch Neurol. 1996;53:428–34.CrossRefPubMedGoogle Scholar
  117. 117.
    Farber NB, Rubin EH, Newcomer JW, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry. 2000;57(12):1165–73.CrossRefPubMedGoogle Scholar
  118. 118.
    Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol. 2001;49(3):355–61.CrossRefPubMedGoogle Scholar
  119. 119.
    Forstl H, Besthorn C, Burns A, et al. Delusional misidentification in Alzheimer’s disease: a summary of clinical and biological aspects. Psychopathology. 1994;27(3–5):194–9.CrossRefPubMedGoogle Scholar
  120. 120.
    Kotrla KJ, Chacko RC, Harper RG, et al. Clinical variables associated with psychosis in Alzheimer’s disease. Am J Psychiatry. 1995;152(9):1377–9.CrossRefPubMedGoogle Scholar
  121. 121.
    Starkstein SE, Vazquez S, Petracca G, et al. A SPECT study of delusions in Alzheimer’s disease. Neurology. 1994;44(11):2055–9.CrossRefPubMedGoogle Scholar
  122. 122.
    Mentis MJ, Weinstein EA, Horwitz B, et al. Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer disease. Biol Psychiatry. 1995;38(7):438–49.CrossRefPubMedGoogle Scholar
  123. 123.
    Sultzer DL, Mahler ME, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1995;7(4):476–84.CrossRefPubMedGoogle Scholar
  124. 124.
    Hirono N, Mori E, Ishii K, et al. Alteration of regional cerebral glucose utilization with delusions in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1998;10(4):433–9.CrossRefPubMedGoogle Scholar
  125. 125.
    Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease. Am J Geriatr Psychiatry. 1998;6(2 Suppl 1):S64–78.CrossRefPubMedGoogle Scholar
  126. 126.
    Strauss ME, Ogrocki PK. Confirmation of an association between family history of affective disorder and the depressive syndrome in Alzheimer’s disease. Am J Psychiatry. 1996;153(10):1340–2.CrossRefPubMedGoogle Scholar
  127. 127.
    Lyketsos CG, Tune LE, Pearlson G, et al. Major depression in Alzheimer’s disease. An interaction between gender and family history. Psychosomatics. 1996;37(4):380–4.CrossRefPubMedGoogle Scholar
  128. 128.
    Bacanu SA, Devlin B, Chowdari KV, et al. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13(7):624–7.CrossRefPubMedGoogle Scholar
  129. 129.
    Ballard C, Massey H, Lamb H, et al. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1997;63(2):273–4.CrossRefPubMedGoogle Scholar
  130. 130.
    Cacabelos R, Rodríguez B, Carrera C, et al. APOE-related frequency of cognitive and noncognitive symptoms in dementia. Methods Find Exp Clin Pharmacol. 1996;18(10):693–706.PubMedGoogle Scholar
  131. 131.
    Holmes C, Arranz MJ, Powell JF, et al. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer’s disease. Hum Mol Genet. 1998;7(9):1507–9.CrossRefPubMedGoogle Scholar
  132. 132.
    Sukonick DL, Pollock BG, Sweet RA, et al. The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol. 2001;58(9):1425–8.CrossRefPubMedGoogle Scholar
  133. 133.
    Sweet RA, Nimgaonkar VL, Kamboh MI, et al. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol. 1998;55(10):1335–40.CrossRefPubMedGoogle Scholar
  134. 134.
    Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzheimer’s disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71(6):777–9.CrossRefPubMedCentralPubMedGoogle Scholar
  135. 135.
    Meins W, Frey A, Thiesemann R. Premorbid personality traits in Alzheimer’s disease: do they predispose to noncognitive behavioral symptoms? Int Psychogeriatr. 1998;10(4):369–78.CrossRefPubMedGoogle Scholar
  136. 136.
    Chatterjee A, Strauss ME, Smyth KA, et al. Personality changes in Alzheimer’s disease. Arch Neurol. 1992;49(5):486–91.CrossRefPubMedGoogle Scholar
  137. 137.
    Lawlor B. Managing behavioural and psychological symptoms of dementia. Br J Psychiatry. 2002;181:463–5.CrossRefPubMedGoogle Scholar
  138. 138.
    Coen RF, Swanwick GR, O'Boyle CA, et al. Behaviour disturbance and other predictors of carer burden in Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12(3):331–6.CrossRefPubMedGoogle Scholar
  139. 139.
    Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46(2):210–5.CrossRefPubMedGoogle Scholar
  140. 140.
    O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5(1):45–52.PubMedGoogle Scholar
  141. 141.
    Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry. 1990;147(8):1049–51.CrossRefPubMedGoogle Scholar
  142. 142.
    Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer’s disease: prospective analyses from the Predictors Study. Neurology. 1994;44:2300–7.CrossRefPubMedGoogle Scholar
  143. 143.
    Stern Y, Mayeux R, Sano M, et al. Predictors of disease course in patients with probable Alzheimer’s disease. Neurology. 1987;37:1649–53.CrossRefPubMedGoogle Scholar
  144. 144.
    Beeri MS, Werner P, Davidson M, et al. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2002;17(5):403–8.CrossRefPubMedGoogle Scholar
  145. 145.
    Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59(11):1721–9.CrossRefPubMedGoogle Scholar
  146. 146.
    Robert PH, Verhey FR, Byrne EJ, et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry. 2005;20(7):490–6.CrossRefPubMedGoogle Scholar
  147. 147.
    Jeon YH, Sansoni J, Low LF, et al. Recommended measures for the assessment of behavioral disturbances associated with dementia. Am J Geriatr Psychiatry. 2011;19(5):403–15.CrossRefPubMedGoogle Scholar
  148. 148.
    Lanari A, Amenta F, Silvestrelli G, et al. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer’s disease. Mech Ageing Dev. 2006;127(2):158–65.CrossRefPubMedGoogle Scholar
  149. 149.
    Livingston G, Johnston K, Katona C, et al. Old age task force of the world federation of biological psychiatry. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996–2021.CrossRefPubMedGoogle Scholar
  150. 150.
    Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946–53.CrossRefPubMedGoogle Scholar
  151. 151.
    Seitz DP, Brisbin S, Herrmann N, et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. J Am Med Dir Assoc. 2012;13(6):503–6.CrossRefPubMedGoogle Scholar
  152. 152.
    Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2009;4:1–128.Google Scholar
  153. 153.
    Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.CrossRefPubMedGoogle Scholar
  154. 154.
    Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness and safety of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.CrossRefPubMedGoogle Scholar
  155. 155.
    Mittal V, Kurup L, Williamson D, et al. Review: risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(1):10–28.CrossRefPubMedGoogle Scholar
  156. 156.
    Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91–103.CrossRefPubMedGoogle Scholar
  157. 157.
    Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330(7489):445.CrossRefPubMedCentralPubMedGoogle Scholar
  158. 158.
    Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66(9):1090–6.CrossRefPubMedGoogle Scholar
  159. 159.
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.CrossRefPubMedGoogle Scholar
  160. 160.
    Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.CrossRefPubMedGoogle Scholar
  161. 161.
    Reus V, Fochtmann L, Eyler A, et al. The American psychiatric association practice guideline on the use of Antipsychotics to treat agitation or Psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–6.CrossRefPubMedGoogle Scholar
  162. 162.
    Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;16(2):CD008191.Google Scholar
  163. 163.
    Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(3):169–83.CrossRefPubMedGoogle Scholar
  164. 164.
    Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev. 2004;2:CD003945.Google Scholar
  165. 165.
    Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293–308.CrossRefPubMedGoogle Scholar
  166. 166.
    Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210–6.CrossRefPubMedGoogle Scholar
  167. 167.
    Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42(1):32–8.CrossRefPubMedGoogle Scholar
  168. 168.
    Tampi RR, Tampi DJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29(7):565–74.CrossRefPubMedGoogle Scholar
  169. 169.
    Jansen S, Forbes D, Duncan V, et al. Melatonin for cognitive impairment. Cochrane Database Syst Rev. 2006;25(1):CD003802.Google Scholar
  170. 170.
    Desk Reference to the Diagnostic Criteria from DSM-5. Washington DC: American Psychiatric Association. 2013. P. 292–8.Google Scholar
  171. 171.
    Saxena S, Lawley D. Delirium in the elderly: a clinical review. Postgrad Med J. 2009;85(1006):405–13.CrossRefPubMedGoogle Scholar
  172. 172.
    Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat. Rev Neurol. 2009;5(4):210–20.CrossRefGoogle Scholar
  173. 173.
    Khan BA, Zawahiri M, Campbell NL, et al. Delirium in hospitalized patients: implications of current evidence on clinical practice and future avenues for research-a systematic evidence review. J Hosp Med. 2012;7(7):580–9.CrossRefPubMedCentralPubMedGoogle Scholar
  174. 174.
    Miller MO. Evaluation and management of delirium in hospitalized older patients. Am Fam Physician. 2008;78(11):1265–70.PubMedGoogle Scholar
  175. 175.
    Inouye SK. Predisposing and precipitating factors for delirium in hospitalized older patients. Dement Geriatr Cogn Disord. 1999;10(5):393–400.CrossRefPubMedGoogle Scholar
  176. 176.
    Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA. 1996;275(11):852–7.CrossRefPubMedGoogle Scholar
  177. 177.
    Laurila JV, Laakkonen ML, Tilvis RS, et al. Predisposing and precipitating factors for delirium in a frail geriatric population. J Psychosom Res. 2008;65(3):249–54.CrossRefPubMedGoogle Scholar
  178. 178.
    Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006;35(4):350–64.CrossRefPubMedGoogle Scholar
  179. 179.
    Rockwood K, Cosway S, Carver D, et al. The risk of dementia and death after delirium. Age Ageing. 1999;28(6):551–6.CrossRefPubMedGoogle Scholar
  180. 180.
    Leslie DL, Marcantonio ER, Zhang Y, et al. One-year health care costs associated with delirium in the elderly population. Arch Intern Med. 2008;168(1):27–32.CrossRefPubMedCentralPubMedGoogle Scholar
  181. 181.
    Young J, Inouye SK. Delirium in older people. BMJ. 2007;334(7598):842–6.CrossRefPubMedCentralPubMedGoogle Scholar
  182. 182.
    Wong CL, Holroyd-Leduc J, Simel DL, et al. Does this patients have delirium?: value of bedside instruments. JAMA. 2010;304(7):779–86.CrossRefPubMedGoogle Scholar
  183. 183.
    Cole MG. Delirium in elderly patients. Am J Geriatr Psychiatry. 2004;12(1):7–21.CrossRefPubMedGoogle Scholar
  184. 184.
    Luetz A, Heymann A, Radtke FM, et al. Different assessment tools for intensive care unit delirium: which score to use? Crit Care Med. 2010;38(2):409–18.CrossRefPubMedGoogle Scholar
  185. 185.
    Adamis D, Sharma N, Whelan PJ, et al. Delirium scales: a review of current evidence. Aging Ment Health. 2010;14(5):543–55.CrossRefPubMedGoogle Scholar
  186. 186.
    Zou Y, Cole MG, Primeau FJ, et al. Detection and diagnosis of delirium in the elderly: psychiatric diagnosis, confusion assessment method, or consensus diagnosis? Int Psychogeriatr. 1998;10(3):303–8.CrossRefPubMedGoogle Scholar
  187. 187.
    Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669–76.CrossRefPubMedGoogle Scholar
  188. 188.
    Rizzo JA, Bogardus ST, Leo-Summers L, et al. Multicomponent targeted intervention to prevent delirium in hospitalized older patients: what is the economic value? Med Care. 2001;39:740–52.CrossRefPubMedGoogle Scholar
  189. 189.
    Leslie DL, Zhang Y, Bogardus ST, et al. Consequences of preventing delirium in hospitalized older adults on nursing home costs. J Am Geriatr Soc. 2005;53(3):405–9.CrossRefPubMedGoogle Scholar
  190. 190.
    Marcantonio ER, Flacker JM, Wright RJ, et al. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc. 2001;49(5):516–22.CrossRefPubMedGoogle Scholar
  191. 191.
    Caplan GA, Coconis J, Board N, et al. Does home treatment affect delirium? A randomised controlled trial of rehabilitation of elderly and care at home or usual treatment (The REACH-OUT trial). Age Ageing. 2006;35(1):53–60.CrossRefPubMedGoogle Scholar
  192. 192.
    Milisen K, Lemiengre J, Braes T, et al. Multicomponent intervention strategies for managing delirium in hospitalized older people: systematic review. J Adv Nurs. 2005;52(1):79–90.CrossRefPubMedGoogle Scholar
  193. 193.
    Clegg A, Siddiqi N, Heaven A, Young J, et al. Interventions for preventing delirium in older people in institutional long-term care. Cochrane Database Syst Rev. 2014;1:CD009537.Google Scholar
  194. 194.
    Martinez F, Tobar C, Hill N. Preventing delirium: should non-pharmacological, multicomponent interventions be used? A systematic review and meta-analysis of the literature. Age Ageing. 2015;44(2):196–204.CrossRefPubMedGoogle Scholar
  195. 195.
    Teslyar P, Stock VM, Wilk CM, et al. Prophylaxis with antipsychotic medication reduces the risk of post-operative delirium in elderly patients: a meta-analysis. Psychosomatics. 2013;54(2):124–31.CrossRefPubMedGoogle Scholar
  196. 196.
    Fok MC, Sepehry AA, Frisch L, et al. Do antipsychotics prevent postoperative delirium? A systematic review and meta-analysis. Int J Geriatr Psychiatry. 2015;30(4):333–44.CrossRefPubMedGoogle Scholar
  197. 197.
    Cole MG, Fenton FR, Engelsmann F, et al. Effectiveness of geriatric psychiatry consultation in an acute care hospital: a randomized clinical trial. J Am Geriatr Soc. 1991;39(12):1183–8.CrossRefPubMedGoogle Scholar
  198. 198.
    Cole MG, Primeau FJ, Bailey RF, et al. Systematic intervention for elderly inpatients with delirium: a randomized trial. CMAJ. 1994;151(7):965–70.PubMedCentralPubMedGoogle Scholar
  199. 199.
    Milisen K, Foreman MD, Abraham IL, et al. A nurse-led interdisciplinary intervention program for delirium in elderly hip-fracture patients. J Am Geriatr Soc. 2001;49(5):523–32.CrossRefPubMedGoogle Scholar
  200. 200.
    Cole MG, McCusker J, Bellavance F, et al. Systematic detection and multidisciplinary care of delirium in older medical inpatients: a randomized trial. CMAJ. 2002;167(7):753–9.PubMedCentralPubMedGoogle Scholar
  201. 201.
    Lonergan E, Britton AM, Luxenberg J, et al. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007;2:CD005594.Google Scholar
  202. 202.
    Ozbolt LB, Paniagua MA, Kaiser RM. Atypical antipsychotics for the treatment of delirious elders. J Am Med Dir Assoc. 2008;9(1):18–28.CrossRefPubMedGoogle Scholar
  203. 203.
    Liptzin B, Laki A, Garb JL, et al. Donepezil in the prevention and treatment of post-surgical delirium. Am J Geriatr Psychiatry. 2005;13(12):1100–6.CrossRefPubMedGoogle Scholar
  204. 204.
    Sampson EL, Raven PR, Ndhlovu PN, et al. A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int J Geriatr Psychiatry. 2007;22(4):343–9.CrossRefPubMedGoogle Scholar
  205. 205.
    Gamberini M, Bolliger D, Lurati Buse GA, et al. Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery-a randomized controlled trial. Crit Care Med. 2009;37(5):1762–8.CrossRefPubMedGoogle Scholar
  206. 206.
    Overshott R, Vernon M, Morris J, et al. Rivastigmine in the treatment of delirium in older people: a pilot study. Int Psychogeriatr. 2010;22(5):812–8.CrossRefPubMedGoogle Scholar
  207. 207.
    Chakraborti D, Tampi DJ, Tampi RR. Melatonin and Melatonin Agonist for Delirium in the Elderly Patients. Am J Alzheimers Dis Other Demen. 2015;30(2):119–29.CrossRefPubMedGoogle Scholar
  208. 208.
    Lonergan E, Luxenberg J, Areosa SA. Benzodiazepines for delirium. Cochrane Database Syst Rev. 2009;4:CD006379.Google Scholar
  209. 209.
    Treatment of Patients with Delirium. Accessed 5 Jun 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Rajesh R. Tampi
    • 1
  • Deena J. Tampi
    • 2
  • Wynnelena C. Canio
    • 3
  • Poorvanshi Alag
    • 1
  • Dhweeja Dasarathy
    • 4
  • Joel P. Dey
    • 5
  1. 1.Case Western Reserve University School of Medicine and MetrohealthClevelandUSA
  2. 2.Diamond HealthcareRichmondUSA
  3. 3.Semel Institute for Neuroscience and Human Behavior, UCLA School of MedicineLos AngelesUSA
  4. 4.Harvard UniversityCambridgeUSA
  5. 5.MetrohealthClevelandUSA

Personalised recommendations